Here are Tuesday's biggest analyst calls: Nvidia, Tesla, Micron, Costco, StubHub, Broadcom, CrowdStrike & more

Wall Street analysts issued a broadly constructive set of calls, with multiple upgrades and higher price targets across semiconductors, software, healthcare, and payments. Notable moves include Micron’s PT raised to $840 from $425, Nvidia to $325 from $295, CrowdStrike to $650 from $550, and Jazz Pharmaceuticals to $307 from $188, signaling stronger demand, AI upside, and improving business resilience. The article is sentiment-positive overall but mainly reflects analyst opinion rather than new company-reported fundamentals.

Analysis

This is a broad-risk-on dispersion tape, but the important second-order read is that the market is rewarding earnings durability and pricing power more than pure growth. The most actionable theme is semis: a constructive read-through for MU, NVDA, AVGO, and UMC suggests investors are willing to underwrite another leg of capex and inventory rebuilding, which typically feeds back into equipment, packaging, and memory-adjacent suppliers over the next 1-2 quarters. If memory pricing is inflecting this hard, the trade is not just long memory names; it is long the whole AI buildout cohort that benefits from lower BOM anxiety and better visibility into hyperscaler spend.

Healthcare and specialty financials look like a separate, less crowded source of alpha. JAZZ and PGNY are being re-rated on resilience rather than cyclical acceleration, which usually matters more for multiple expansion than headline growth because it compresses the discount rate applied to future cash flows. AGO and BAP fit the same pattern: the market is being nudged toward balance-sheet quality and underwriting discipline, which is favorable in a regime where consensus still expects some macro slowdown but not a credit event.

The contrarian tell is that TSLA remains the obvious weak link in a tape otherwise characterized by positive estimate revisions. With sentiment effectively flat, the market is signaling that product milestones alone are not enough without evidence of monetization; that makes TSLA more of a catalyst-trading name over the next 4-8 weeks than a fundamental momentum long. COST is similarly interesting: the stock may already discount the defensiveness, so upside likely depends on a non-operational catalyst rather than another modest comp beat.

Near-term risks are mainly earnings-related and valuation-related rather than macro. CRWD, NVDA, and AVGO can all pull back sharply if guidance is merely good instead of great, because the multiple is now doing more of the work than the numbers. For the bullish calls with limited room for disappointment, the cleanest expression is pairs and call spreads rather than outright longs, especially into earnings windows over the next 1-3 weeks.

Key Decisions for Investors

• Stay long MU vs short a weaker analog/semi basket for 4-8 weeks; thesis is that memory pricing inflection can surprise on gross margin leverage, with better asymmetric upside than owning the index outright.
• Initiate a long NVDA / short TSLA pair for the next earnings cycle; NVDA has a visible demand catalyst, while TSLA lacks a comparable near-term monetization surprise, creating a cleaner relative-value setup.
• Use call spreads in CRWD or AVGO into earnings rather than cash equity; implied upside exists, but valuation leaves little room for a guide-down, so defined-risk options improve reward/risk.
• Buy JAZZ on pullbacks over the next 1-2 weeks, but size modestly; the re-rating thesis is durable if base business resilience holds, yet execution on the new drug is still a medium-horizon catalyst.
• For defensive exposure, prefer AMT and COST over broad consumer/REIT baskets; both can work as quality compounders, but wait for better entry points because the market is already partially paying for the safety premium.